Cellulitis and Skin and Soft Tissue Infections

• Bacterial inoculation and initial colonization: Causative organisms (most commonly Streptococcus pyogenes and Staphylococcus aureus) must breach the skin barrier through macroscopic breaks (cuts, abrasions, surgical wounds) or microscopic disruptions (interdigital maceration, tinea pedis). The bacteria elaborate adhesins (such as hyaluronic acid capsule in S. pyogenes and clumping factor in S. aureus) that promote binding to fibronectin and other host matrix proteins. Once established, bacteria proliferate in tissue planes with minimal initial immune containment.

• Virulence factor production and immune evasion: S. pyogenes secretes multiple streptolysins (O and S), which create pores in host cell membranes and cause direct myonecrosis and leukocyte lysis, explaining the poor demarcation of streptococcal cellulitis borders. The organism produces hyaluronidase and streptokinase (fibrinolytic enzymes) that degrade hyaluronic acid in connective tissue matrix and lyse fibrin clots, respectively, facilitating rapid horizontal spread through tissue planes. S. aureus produces α-toxin (α-hemolysin) and Panton-Valentine leukocidin (PVL), particularly in community-associated methicillin-resistant S. aureus (CA-MRSA), which directly lyse neutrophils and macrophages, rendering the local immune response ineffective. Protein A on staphylococcal surface binds to the Fc portion of IgG, blocking opsonization and complement deposition. These factors collectively explain why cellulitis spreads diffusely rather than forming discrete, walled-off abscesses.

• Inflammatory cascade and tissue edema: Bacterial lipopolysaccharides (LPS) and peptidoglycans activate pattern recognition receptors (TLRs) on tissue macrophages and endothelial cells, triggering nuclear factor-κB (NF-κB) signaling and massive release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8). These cytokines upregulate adhesion molecules (ICAM-1, VCAM-1, selectins) on vascular endothelium, promoting neutrophil extravasation. Complement cascade activation via classical, alternative, and lectin pathways generates C5a, a potent neutrophil chemoattractant, creating a self-perpetuating inflammatory gradient that recruits additional immune cells. Increased vascular permeability from inflammatory mediators (bradykinin, leukotrienes, prostaglandins) causes fluid extravasation into interstitial space, manifesting clinically as edema and erythema. The poor demarcation of cellulitis (versus abscess with clear border) reflects this diffuse inflammatory response without tissue necrosis or liquefactive center formation.

• Host defense compromise and progression: Underlying conditions that impair lymphatic drainage (previous lymph node dissection, morbid obesity, chronic venous insufficiency) allow bacterial proliferation and reduce local antibiotic delivery. Diabetes mellitus impairs neutrophil chemotaxis and oxidative burst, reducing bacterial killing. Immunosuppressive states (HIV with CD4 <200, transplantation, chronic corticosteroids) diminish T-cell recruitment and Th1 response polarization. Break-through bacteremia occurs when bacterial load overwhelms local immunity and tissue barriers erode, allowing entry into dermis and subcutaneous vessels.

• Transition to necrotizing infection: If host immunity fails or virulence is extreme, cellulitis may progress to necrotizing fasciitis, characterized by rapid spread along fascial planes with tissue necrosis. Bacterial hyaluronidase production, coupled with inadequate neutrophil response in immunocompromised patients, permits deeper tissue invasion. Polymicrobial infections (particularly with anaerobes and Clostridium species after trauma or surgery) produce synergistic toxins that cause exponential tissue destruction and systemic toxicity disproportionate to bacterial burden.

• Streptococcus pyogenes (Group A Streptococcus, GAS) accounts for 60-80% of cellulitis cases, particularly when borders are diffuse and ill-defined. GAS is an obligate human pathogen spread through respiratory or skin contact and is especially common in tropical and warm climates or during summer months. Historically dominated acute cellulitis; still the most common cause of non-suppurative cellulitis in immunocompetent hosts.

• Staphylococcus aureus, both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA), has emerged as a major pathogen over the past two decades. MSSA remains the predominant staphylococcal cause of cellulitis, but CA-MRSA prevalence varies geographically. MRSA is increasingly common in healthcare settings, among injection drug users, and in certain geographic regions (especially southwestern United States). Staphylococcal cellulitis may present with more localized erythema or suppurative features (abscesses) compared to streptococcal disease.

• Beta-hemolytic streptococci (Groups B, C, G) cause cellulitis less frequently than GAS but are important in specific populations: Streptococcus agalactiae (GBS) in neonates with maternal colonization and in elderly or immunocompromised hosts with underlying malignancy or diabetes. Group C and G streptococci typically affect elderly patients with underlying lymphatic compromise.

• Gram-negative organisms (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae) are uncommon causes of community-acquired cellulitis but emerge in specific clinical contexts: immunocompromised patients (especially those with neutropenia <500 cells/μL), puncture wounds with freshwater or saltwater exposure (Pseudomonas), and diabetic foot ulcers. Vibrio species cause cellulitis following exposure to contaminated saltwater or shellfish in coastal regions.

• Anaerobes and polymicrobial infection occur in the setting of traumatic wounds (particularly crush injuries or wounds heavily contaminated with soil or feces), animal bites, surgery, or immunosuppression. Clostridium perfringens can cause rapidly progressive, gas-forming cellulitis (crepitus) with systemic toxicity within 24-48 hours of inoculation.

• Risk factors for cellulitis include:
• Lymphatic obstruction: prior lymph node dissection (axillary or inguinal), morbid obesity, chronic venous insufficiency, lipodermatosclerosis
• Skin barrier disruption: tinea pedis or other fungal infections, interdigital maceration, dermatitis, venous or arterial ulcers, surgical wounds
• Immunosuppression: HIV with CD4 <200 cells/μL, transplant recipients, chronic corticosteroid use (≥20 mg prednisone daily), TNF-α inhibitors, chemotherapy
• Systemic conditions: diabetes mellitus (particularly with peripheral neuropathy), chronic kidney disease, malnutrition, cirrhosis
• Extremes of age: very young children and elderly patients have higher incidence
• Injection drug use: risk of polymicrobial skin infections, bacteremia, endocarditis
• Previous cellulitis: recurrent cellulitis indicates underlying predisposing factor and carries risk of repeated episodes

• Erythema is the cardinal sign, typically appearing as ill-defined, non-blanching erythema in streptococcal cellulitis. The border is often indistinct and spreads centrifugally, sometimes with visible lymphangitis (red streaking along lymphatic vessels toward regional nodes). In staphylococcal cellulitis, erythema may be more localized, particularly if abscess formation occurs. Erythema represents underlying vasodilation and inflammatory cell infiltration in the dermis and subcutaneous tissue.

• Edema and induration result from increased vascular permeability and inflammatory cell extravasation. Affected tissue appears swollen, tense, and may demonstrate pitting if significant fluid accumulation occurs. Palpation typically reveals non-fluctuant firmness (distinguishing cellulitis from abscess with fluctuant center).

• Warmth of affected area reflects increased local blood flow and metabolic activity of inflammatory cells. Warmth is best assessed by comparison to contralateral unaffected skin.

• Local pain and tenderness vary in intensity and may be disproportionate to severity of visible inflammation in rapidly progressive cases. Pain results from tissue edema, leukocyte infiltration, and cytokine-mediated inflammation. Severe pain out of proportion to clinical findings should raise concern for necrotizing fasciitis.

• Systemic symptoms include fever (present in 30-50% of cases), malaise, fatigue, and myalgias, reflecting circulating cytokine response and potential early bacteremia. High fever (>39.5°C or 103.1°F) suggests more severe infection or systemic toxicity.

• Lymphangitis and regional lymphadenopathy occur in 40-60% of cases, appearing as red streaks tracking toward regional lymph nodes (e.g., inguinal lymph node enlargement with lower extremity cellulitis). Lymphadenopathy reflects reactive immune activation but can be confused with lymphatic involvement in skin lymphomas.

• Lower extremity predominance: cellulitis most commonly affects legs (70-80% of cases), particularly the tibia and ankle regions, often triggered by tinea pedis or minor trauma. Facial cellulitis (especially "periorbital" or preseptal cellulitis) presents acutely with rapid periocular edema and erythema; orbital cellulitis with eye movement pain and ophthalmoplegia represents medical emergency.

• Perioral/perianal cellulitis in young children (ages 2-5 years) classically presents with blue-purple discoloration, often caused by Streptococcus pneumoniae bacteremia; incidence has decreased significantly with pneumococcal vaccination.

• Rapid progression and demarcation characteristics: streptococcal cellulitis classically presents with acute onset over hours, diffuse borders, and rapid spread; staphylococcal cellulitis may have more abrupt localized erythema with potential suppuration. Mixed infections or MRSA may present with areas of fluctuance or abscess formation adjacent to cellulitis.

• Clinical variants: "Cellulitis surrounding an abscess" represents a mixed picture of surrounding inflammation with central purulent collection; "erysipelas" (now considered superficial cellulitis) involves upper dermis with sharp demarcation and raised borders, most commonly on face; "impetigo" is superficial pyoderma with honey-crusted lesions in children, typically non-bullous (GAS) or bullous (MSSA).

• Clinical diagnosis based on signs and symptoms is the standard approach; cellulitis is primarily diagnosed clinically without requirement for microbiological confirmation in most uncomplicated cases. The combination of acute onset erythema, edema, warmth, and tenderness in a localized region with or without systemic symptoms is highly sensitive (though not specific for organism type). History of skin barrier disruption, preceding tinea pedis, or recurrent infections in the same site strengthens diagnosis.

• Blood cultures are recommended in hospitalized patients (especially those with systemic toxicity, immunosuppression, or signs of bacteremia such as fever >39°C), and may be positive in 5-15% of cellulitis cases. Blood culture sensitivity is limited but can identify bacteremia and guide therapy if pathogen is resistant to empiric regimen. Positive blood cultures in cellulitis (particularly if multiple organisms or contaminants are isolated) warrant investigation for underlying endocarditis, particularly in injection drug users.

• Gram stain and culture of aspirate obtained from advancing margin of cellulitis (using 18-gauge needle infiltrated with sterile saline and aspirated before withdrawal) can provide organism identification but requires experienced laboratory technicians and is positive in only 10-20% of cases; not routinely recommended. Culture may be more valuable in immunocompromised patients, polymicrobial infections suspected, or poor response to initial therapy.

• Complete blood count (CBC) typically shows leukocytosis with left shift (elevated neutrophils, immature forms), reflecting inflammatory response. White blood cell count may exceed 20,000 cells/μL in severe infections or rapidly progressive disease; however, normal WBC does not exclude cellulitis, particularly in immunocompromised hosts.

• Inflammatory markers (erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]) are elevated in cellulitis but lack specificity for organism type or infection severity; used to trend disease progression or response to therapy rather than for diagnosis. CRP >10 mg/L suggests bacterial infection but is also elevated in many inflammatory conditions.

• Imaging is not routinely necessary for diagnosis of uncomplicated cellulitis but serves specific purposes:
• Ultrasound with high-frequency transducer can detect fluid collections (abscess, loculated pus) and help distinguish cellulitis from abscess requiring drainage; sensitivity for abscess detection 85-95%.
• MRI is most sensitive (95-100%) for detecting necrotizing fasciitis (showing fascial enhancement, fluid tracking along tissue planes) and for evaluating osteomyelitis in diabetic foot infections; typically reserved for diagnostic uncertainty or when necrotizing infection suspected.
• X-ray is performed to evaluate for gas (crepitus) when Clostridium or other gas-forming organisms suspected or if osteomyelitis involvement is concern; demonstrates subcutaneous air as dark streaks within fat planes.

• Differential diagnosis considerations:
• Abscess/pyogenic collection: presents with more localized, fluctuant area; ultrasound or needle aspiration diagnostic
• Erysipelas: more superficial involvement with sharply demarcated borders and raised edges; typically streptococcal
• Necrotizing fasciitis: rapid progression with pain out of proportion to findings, systemic toxicity, crepitus, skin color changes (purple/gray); high mortality (20-30%); requires emergent imaging (MRI preferred) and surgical exploration
• Contact dermatitis: absence of systemic symptoms, exposure history, less dramatic edema
• Venous insufficiency/stasis: chronic presentation, skin changes (lipodermatosclerosis, hyperpigmentation), absence of acute inflammation
• Lymphedema: chronic progressive swelling without acute inflammation or fever
• DVT: unilateral leg swelling with potential calf pain, absence of erythema/warmth; ultrasound diagnostic

• First-line empiric antibiotic therapy for non-purulent cellulitis (presumed streptococcal or MSSA):
• Outpatient, oral therapy: Cephalexin 500 mg PO four times daily (or PO cephalosporin alternative such as cefadroxil 1000 mg daily) for 10-14 days. Cephalosporins have excellent coverage for both GAS and MSSA and are typically recommended because of their reliability and safety profile. Penicillin V 500 mg PO four times daily is an older alternative with good streptococcal coverage but inferior staphylococcal coverage.
• Inpatient, intravenous therapy: Cefazolin 1-2 grams IV every 6-8 hours or nafcillin 1-2 grams IV every 4-6 hours (if MSSA coverage needed with superior activity to cephalosporins) for mild-to-moderate cellulitis. Beta-lactam allergy: vancomycin 15-20 mg/kg IV every 8-12 hours (AUC-guided dosing, AUC/MIC 400-600 per the 2020 IDSA/ASHP consensus; trough-only targets are no longer recommended). Dosing adjustments required

Local and deep-tissue extension

• Abscess formation: liquefactive necrosis walls off within the inflamed dermis, signaled by a fluctuant, point-tender center or a hypoechoic collection on point-of-care ultrasound. Per the IDSA 2014 skin and soft tissue infection guideline, incision and drainage — not antibiotics alone — is the primary therapy.
• Necrotizing fasciitis / myonecrosis (surgical emergency): hyaluronidase and exotoxin-mediated spread along avascular fascial planes with thrombosis of perforating vessels produces pain out of proportion, woody induration extending beyond the erythema, bullae, dusky or anesthetic skin, and crepitus. Rising creatine kinase, marked leukocytosis, and hyponatremia support the diagnosis. Immediate surgical exploration is both diagnostic and therapeutic; imaging must never delay the operating room.
• Osteomyelitis and septic arthritis: contiguous spread through a diabetic foot ulcer or over a joint; suspect with ulcer probing to bone, non-healing wound, or a joint effusion with restricted motion.

Systemic complications

• Bacteremia and sepsis (emergency): breach of dermal capillaries seeds the bloodstream; hypotension, tachypnea, and lactate elevation demand fluids and prompt IV antibiotics.
• Streptococcal or staphylococcal toxic shock syndrome (emergency): superantigen-driven polyclonal T-cell activation causes shock with a diffuse macular rash and multiorgan failure disproportionate to local findings.
• Post-streptococcal glomerulonephritis: immune-complex deposition weeks after GAS pyoderma, with cola-colored urine and low C3. Acute rheumatic fever does not follow skin infection.
• Cavernous sinus thrombosis / orbital cellulitis (emergency): valveless facial veins allow retrograde spread; ophthalmoplegia, proptosis, and pain with eye movement mandate urgent CT of the orbits and IV antibiotics.
• Chronic lymphedema with recurrence: each episode scars lymphatics, creating a self-reinforcing cycle; IDSA supports suppressive penicillin or a first-generation cephalosporin after repeated episodes plus aggressive treatment of tinea pedis.

Treatment-related

• Vancomycin nephrotoxicity: risk rises with AUC above target and with concurrent piperacillin-tazobactam; monitor creatinine.
• **Clindamycin and C. difficile colitis**: new watery diarrhea after therapy.
• TMP-SMX hyperkalemia and rash: amiloride-like tubular effect; also SJS/TEN.

• Purulent versus non-purulent drives empiric coverage: the IDSA 2014 SSTI framework splits management on drainage. Purulent (abscess, furuncle) implies S. aureus including CA-MRSA — incision and drainage first, add trimethoprim-sulfamethoxazole or doxycycline for moderate disease. Non-purulent cellulitis is predominantly beta-hemolytic streptococcal — cephalexin or cefazolin. Routinely adding MRSA coverage to simple non-purulent cellulitis is the classic distractor.
• Pain out of proportion to exam is the single most tested phrase: the best next step is emergent surgical consultation for exploration, not MRI, not LRINEC scoring, not broader antibiotics. Adjunctive therapy is broad-spectrum antibiotics plus clindamycin, added because it is a protein-synthesis inhibitor that shuts down exotoxin production regardless of bacterial growth phase (the Eagle effect explains why penicillin alone underperforms in high-inoculum GAS infection).
• Bilateral lower-extremity "cellulitis" is almost never cellulitis: think stasis dermatitis or lipodermatosclerosis (pseudocellulitis). True cellulitis is unilateral and usually febrile.
• Erythema may expand in the first 24–48 hours of appropriate therapy as killed organisms release inflammatory mediators; if the patient is afebrile and improving systemically, do not escalate antibiotics.
• Exposure history names the organism: saltwater or raw oysters in a cirrhotic patient → Vibrio vulnificus with hemorrhagic bullae (doxycycline plus a third-generation cephalosporin); freshwater → Aeromonas; cat bite → Pasteurella multocida (amoxicillin-clavulanate); hot tub → Pseudomonas folliculitis.
• Treat the portal of entry: interdigital tinea pedis is the most commonly missed reversible cause of recurrent leg cellulitis; topical antifungals reduce recurrence.
• Skin infection causes post-streptococcal glomerulonephritis but not acute rheumatic fever — a recurring one-line association.
• Periorbital (preseptal) versus orbital: proptosis, painful or restricted extraocular movements, or diplopia means postseptal disease — obtain contrast CT of the orbits and admit for IV antibiotics.